CompoAtlas

ANIMAL PAK POWDERS (ORANGE)

Food supplement declared in France, decision dated 11 August 2025

ANIMAL PAK POWDERS (ORANGE), from Universal Nutrition Retail BV, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: glutamine 200 mg per day, inulines 125 mg per day, bromélaïne 50 mg per day, papaïne 32 mg per day, flavonoïdes 2.5 mg per day. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
not provided
Food business operator placing the product on the market
Universal Nutrition Retail BV
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Powder
Daily dose
1 cuillère doseuse de 7,09 g.
Directions for use
Mélangez 1 cuillère doseuse à 320 ml de votre boisson préférée au petitdéjeuner ou à tout autre repas
Flavourings
orange

Declaration 338485, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Pinus pinaster AitonEcorceExtrait sec aqueux100 mg
Vitis vinifera L.PépinExtrait sec aqueux25 mg
Ascophyllum nodosum (L.) Le JolisThalleExtrait sec aqueux5.41 mg
Panax quinquefolius L.FruitPoudre (de plantes séchées ou broyées)2.5 mg
Crataegus laevigata (Poir.) DC.FruitExtrait sec aqueux2.5 mg

Substances

NamePer day
glutamine200 mg
inulines125 mg
bromélaïne50 mg
papaïne32 mg
flavonoïdes2.5 mg
lycopène0.5 mg
lutéine0.5 mg

Other active ingredients

NamePer day
Ubiquinonenot declared
L-carnitinenot declared
Inositolnot declared
Bitartrate de cholinenot declared
Chlorhydrate de L-argininenot declared
Taurinenot declared
Protéines de lactosérumnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-pantothenate, calciumPantothenic acid (vitamin B5)no limit (insufficient data)dose annulled by the French Council of State in 2011
D-biotinBiotin (vitamin B8)no limit (insufficient data)dose annulled by the French Council of State in 2011
beta-caroteneβ-Caroteneno limit (insufficient data)no fixed dose
calcium salts of citric acidCalcium2,500 mg800 mg
calcium carbonateCalcium2,500 mg800 mg
Chlorure de chromeChromiumno limit (insufficient data)25 µg
cupric sulphateCopper5,000 µg2,000 µg
pteroylmonoglutamic acidFolate (vitamin B9)1,000 µg200 µg
potassium iodideIodine600 µg150 µg
magnesium oxideMagnesium250 mg300 mg
manganese sulphateManganese8 mg (safe level)3.5 mg
nicotinamideNicotinamide (vitamin B3)900 mg54 mg
sodium seleniteSelenium255 µg50 µg
retinyl acetateVitamin A3,000 µg d'équivalent rétinol800 µg
thiamin mononitrateVitamin B1 (thiamine)no limit (insufficient data)dose annulled by the French Council of State in 2011
cyanocobalaminVitamin B12no adverse effect defineddose annulled by the French Council of State in 2011
riboflavinVitamin B2 (riboflavin)no limit (insufficient data)dose annulled by the French Council of State in 2011
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
D-alpha-tocopheryl acid succinateVitamin E300 mg30 mg
zinc oxideZinc25 mg15 mg

Additives

E133, E129, E955, E950, E551, E296, E322

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Les compléments alimentaires ne doivent pas être utilisés en remplacement d'une alimentation équilibrée et variée et d'un mode de vie sain. Tenir hors de portée des jeunes enfants. Ne pas dépasser la dose journalière recommandée. Réservé aux adultes. Déconseillé aux femmes enceintes ou allaitantes. L''utilisation chez les personnes sous traitement antidiabétique est déconseillée. Déconseillé aux femmes enceintes ou désireuses de l’être Déconseillé aux femmes ménopausées. Déconseillé aux personnes souffrant de troubles de la thyroïde. Usage prolongé déconseillé. Il est important de suivre une alimentation variée et équilibrée et un mode de vie sain. E 129: peut avoir des effets indésirables sur l’activité et l’attention chez les enfants.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Panax quinquefolius L.
    Read the warning, when it applies and the studies cited

    PANAX QUINQUEFOLIUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or digoxin (Brinker 2010; Dasgupta et al. 2007; Elmer et al. 2007; Yuan et al. 2004).

    Sources cited by Health Canada (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dasgupta A, Kang E, Olsen M, Actor JK, Datta P. Interference of Asian, American, and Indian (Ashwagandha) ginseng in serum digoxin measurements by a fluorescence polarization immunoassay can be minimized by using a new enzyme-linked chemiluminescent immunosorbent or turbidimetric assay. Archives of Pathology & Laboratory Medicine 2007;131(4):619-621. PubMed
    • Elmer GW, Lafferty WE, Tyree PT, Lind BK. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. The Annals of Pharmacotherapy 2007;41(10):1617-1624. PubMed
    • Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. American ginseng reduces warfarin's effect in healthy patients. Annals of internal medicine 2004;141(1):23-27. PubMed Randomised trial

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Dascalu et al. 2007; Vuksan et al. 2000a,b,c).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dascalu A, Sievenpiper JL, Jenkins AL, Stavro MP, Leiter LA, Arnason JT, Vuksan V. Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individuals. Canadian Journal of Physiology and Pharmacology 2007;85(9):856-864. PubMed
    • Vuksan V, Xu Z, Jenkins AL, Belgan U, Sievenpiper JL, Leiter LA, Josse RG, Stavro MP.American ginseng (Panax quinquefolium L.) improves long-term glycemic control in type 2 diabetes: double-blind placebo controlled crossover trial. Diabetes 2000a;49 (Suppl.1):A95.

    Condition of application: All products except Glucose levels and Adaptogen - immune system.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

  • Crataegus laevigata (Poir.) DC.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

  • glutamine
    Read the warning, when it applies and the studies cited

    L-Glutamine

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 30 January 2026

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

  • L-carnitine
    Read the warning, when it applies and the studies cited

    L-CARNITINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (CPS 2008).

    Sources cited by Health Canada (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a seizure disorder (CPS 2008).

    Sources cited by Health Canada (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 25 July 2025

  • Taurine
    Read the warning, when it applies and the studies cited

    TAURINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Lopez Ramon et al. 2007; Seghieri et al. 2007).

    Sources cited by Health Canada (2)
    • López Ramón Y Cajal C, Ocampo Martínez R, Couceiro Naveira E, Martínez M. Amino acids in amniotic fluid in the 15th-16th weeks of gestation and preterm labor. The Journal of Maternal-Fetal & Neonatal Medicine: the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2007;20(3):225-231.
    • Seghieri G, Tesi F, Bianchi L, Loizzo A, Saccomanni G, Ghirlanda G, Anichini R, Franconi F. Taurine in women with a history of gestational diabetes. Diabetes Research and Clinical Practice 2007;76(2):187-192. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “ANIMAL PAK POWDERS (ORANGE): composition and regulation”, https://compoatlas.com/en/supplements/products/338485-animal-pak-powders-orange, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line